Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report

Anemia is a prevalent complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Recombinant human erythropoietin (rhEPO) is widely administered to patients both on and off dialysis to manage this anemia. However, despite an initial favorable therapeutic response, a sudden and unexplained decline in hemoglobin levels (Hb) often prompts the need for further diagnostic evaluation. In this context, we report a clinical case involving a 48-year-old male patient who had been undergoing hemodialysis (HD) for two years. During the course of his rhEPO treatment regimen, he developed pure red cell aplasia (PRCA), a rare but serious adverse reaction. Upon recognition of this complication, the administration of rhEPO was promptly discontinued, and the patient was initiated on roxarestat therapy. Remarkably, following nine months of continuous roxarestat treatment, the patient experienced a significant and sustained increase in his Hb levels. This clinical outcome underscores the importance of prompt diagnosis and intervention in cases of EPO-induced PRCA. Furthermore, our findings suggest that roxarestat may serve as a viable and effective therapeutic option for patients with EPO-induced PRCA, potentially obviating the need for immunosuppressive therapy and its associated risks.

Authors

Institutions

Publication Details

Journal
Naunyn-Schmiedeberg s Archives of Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.1007/s00210-026-06084-0
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report

Yumei Zhou, Sufang Jiang, Yunhan Xie, Xinjie Jin et al.
1 links
Naunyn-Schmiedeberg s Archives of Pharmacology
Erythropoietin and Anemia Treatment
article

Roxadustat for treatment of suspected erythropoietin(EPO)-induced pure red cell aplasia in a hemodialysis patient: a case report

Yumei Zhou, Sufang Jiang, Yunhan Xie, Xinjie Jin, Shaowei Song, Ying Jiang
article en

Abstract

Anemia is a prevalent complication in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Recombinant human erythropoietin (rhEPO) is widely administered to patients both on and off dialysis to manage this anemia. However, despite an initial favorable therapeutic response, a sudden and unexplained decline in hemoglobin levels (Hb) often prompts the need for further diagnostic evaluation. In this context, we report a clinical case involving a 48-year-old male patient who had been undergoing hemodialysis (HD) for two years. During the course of his rhEPO treatment regimen, he developed pure red cell aplasia (PRCA), a rare but serious adverse reaction. Upon recognition of this complication, the administration of rhEPO was promptly discontinued, and the patient was initiated on roxarestat therapy. Remarkably, following nine months of continuous roxarestat treatment, the patient experienced a significant and sustained increase in his Hb levels. This clinical outcome underscores the importance of prompt diagnosis and intervention in cases of EPO-induced PRCA. Furthermore, our findings suggest that roxarestat may serve as a viable and effective therapeutic option for patients with EPO-induced PRCA, potentially obviating the need for immunosuppressive therapy and its associated risks.

Naunyn-Schmiedeberg s Archives of Pharmacology
Hubei University of Medicine (CN), Hubei University of Arts and Science (CN), Xiang Yang No.1 People's Hospital (CN)
Good health and well-being
Erythropoietin and Anemia Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon